Small molecule cognitive enhancer reverses age-related memory decline in mice

  1. Karen Krukowski  Is a corresponding author
  2. Amber Nolan
  3. Elma S Frias
  4. Morgane Boone
  5. Gonzalo Ureta
  6. Katherine Grue
  7. Maria-Serena Paladini
  8. Edward Elizarraras
  9. Luz Delgado
  10. Sebastian Bernales
  11. Peter Walter  Is a corresponding author
  12. Susanna Rosi  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Fundación Ciencia & Vida, Chile
  3. Howard Hughes Medical Institute, University of California, San Francisco, United States

Abstract

With increased life expectancy age-associated cognitive decline becomes a growing concern, even in the absence of recognizable neurodegenerative disease. The integrated stress response (ISR) is activated during aging and contributes to age-related brain phenotypes. We demonstrate that treatment with the drug-like small-molecule ISR inhibitor ISRIB reverses ISR activation in the brain, as indicated by decreased levels of activating transcription factor 4 (ATF4) and phosphorylated eukaryotic translation initiation factor eIF2. Furthermore, ISRIB treatment reverses spatial memory deficits and ameliorates working memory in old mice. At the cellular level in the hippocampus, ISR inhibition i) rescues intrinsic neuronal electrophysiological properties, ii) restores spine density and iii) reduces immune profiles, specifically interferon and T cell-mediated responses. Thus, pharmacological interference with the ISR emerges as a promising intervention strategy for combating age-related cognitive decline in otherwise healthy individuals.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Karen Krukowski

    Department of Physical Therapy and Rehabilitation Science, Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, United States
    For correspondence
    karen.krukowski@ucsf.edu
    Competing interests
    No competing interests declared.
  2. Amber Nolan

    Brain and Spinal Injury Center, Department of Pathology,, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Elma S Frias

    Brain and Spinal Injury Center, Department of Pathology,, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  4. Morgane Boone

    Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7807-5542
  5. Gonzalo Ureta

    Fundación Ciencia & Vida, Santiago, Chile
    Competing interests
    Gonzalo Ureta, Works at Fundacion Ciencia & Vida and receive partial funding from Praxis Biotech..
  6. Katherine Grue

    Department of Physical Therapy and Rehabilitation Science, Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Maria-Serena Paladini

    Department of Physical Therapy and Rehabilitation Science, Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  8. Edward Elizarraras

    Department of Physical Therapy and Rehabilitation Science, Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Luz Delgado

    Fundación Ciencia & Vida, Santiago, Chile
    Competing interests
    No competing interests declared.
  10. Sebastian Bernales

    Fundación Ciencia & Vida, Santiago, Chile
    Competing interests
    Sebastian Bernales, SB is an employee of Praxis Biotech..
  11. Peter Walter

    Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
    For correspondence
    peter@walterlab.ucsf.edu
    Competing interests
    Peter Walter, P.W. is an inventor on U.S. Patent 9708247 held by the Regents of the University of California that describes ISRIB and its analogs. Rights to the invention have been licensed by UCSF to Calico. P.W. is a consultant for Praxis Biotech LLC and Black Belt TX Limited..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6849-708X
  12. Susanna Rosi

    Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, United States
    For correspondence
    susanna.rosi@ucsf.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9269-3638

Funding

National Institute on Aging (F32AG054126)

  • Karen Krukowski

National Institutes of Health (R01AG056770)

  • Susanna Rosi

National Center for Advancing Translational Sciences (TL1 TR001871)

  • Amber Nolan

National Institute of Neurological Disorders and Stroke (K08NS114170)

  • Amber Nolan

Howard Hughes Medical Institute

  • Peter Walter

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of California, San Francisco.(Protocol 170302).

Copyright

© 2020, Krukowski et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 49,495
    views
  • 4,541
    downloads
  • 117
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Karen Krukowski
  2. Amber Nolan
  3. Elma S Frias
  4. Morgane Boone
  5. Gonzalo Ureta
  6. Katherine Grue
  7. Maria-Serena Paladini
  8. Edward Elizarraras
  9. Luz Delgado
  10. Sebastian Bernales
  11. Peter Walter
  12. Susanna Rosi
(2020)
Small molecule cognitive enhancer reverses age-related memory decline in mice
eLife 9:e62048.
https://doi.org/10.7554/eLife.62048

Share this article

https://doi.org/10.7554/eLife.62048

Further reading

    1. Computational and Systems Biology
    2. Neuroscience
    Brian DePasquale, Carlos D Brody, Jonathan W Pillow
    Research Article Updated

    Accumulating evidence to make decisions is a core cognitive function. Previous studies have tended to estimate accumulation using either neural or behavioral data alone. Here, we develop a unified framework for modeling stimulus-driven behavior and multi-neuron activity simultaneously. We applied our method to choices and neural recordings from three rat brain regions—the posterior parietal cortex (PPC), the frontal orienting fields (FOF), and the anterior-dorsal striatum (ADS)—while subjects performed a pulse-based accumulation task. Each region was best described by a distinct accumulation model, which all differed from the model that best described the animal’s choices. FOF activity was consistent with an accumulator where early evidence was favored while the ADS reflected near perfect accumulation. Neural responses within an accumulation framework unveiled a distinct association between each brain region and choice. Choices were better predicted from all regions using a comprehensive, accumulation-based framework and different brain regions were found to differentially reflect choice-related accumulation signals: FOF and ADS both reflected choice but ADS showed more instances of decision vacillation. Previous studies relating neural data to behaviorally inferred accumulation dynamics have implicitly assumed that individual brain regions reflect the whole-animal level accumulator. Our results suggest that different brain regions represent accumulated evidence in dramatically different ways and that accumulation at the whole-animal level may be constructed from a variety of neural-level accumulators.

    1. Genetics and Genomics
    2. Neuroscience
    Tanya Wolff, Mark Eddison ... Gerald M Rubin
    Research Article

    The central complex (CX) plays a key role in many higher-order functions of the insect brain including navigation and activity regulation. Genetic tools for manipulating individual cell types, and knowledge of what neurotransmitters and neuromodulators they express, will be required to gain mechanistic understanding of how these functions are implemented. We generated and characterized split-GAL4 driver lines that express in individual or small subsets of about half of CX cell types. We surveyed neuropeptide and neuropeptide receptor expression in the central brain using fluorescent in situ hybridization. About half of the neuropeptides we examined were expressed in only a few cells, while the rest were expressed in dozens to hundreds of cells. Neuropeptide receptors were expressed more broadly and at lower levels. Using our GAL4 drivers to mark individual cell types, we found that 51 of the 85 CX cell types we examined expressed at least one neuropeptide and 21 expressed multiple neuropeptides. Surprisingly, all co-expressed a small molecule neurotransmitter. Finally, we used our driver lines to identify CX cell types whose activation affects sleep, and identified other central brain cell types that link the circadian clock to the CX. The well-characterized genetic tools and information on neuropeptide and neurotransmitter expression we provide should enhance studies of the CX.